A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 5517-5517
Keyword(s):
Phase Ii
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 12
(1)
◽
pp. 48-54